Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo

被引:260
作者
Colombo, S
Soranzo, N
Rotger, M
Sprenger, R
Bleiber, G
Furrer, H
Buclin, T
Goldstein, D
Décosterd, L
Telenti, A [1 ]
机构
[1] Univ Hosp, Inst Microbiol, Lausanne, Switzerland
[2] Univ Hosp, Div Clin Pharmacol, Lausanne, Switzerland
[3] UCL, Ctr Populat Genet & Human Hlth, London WC1E 6BT, England
[4] Epidauros Biotechnol AG, Bernried, Germany
[5] Univ Hosp, Div Infect Dis, Bern, Switzerland
关键词
pharmacogenetics; haplotypes; tagging SNPs; nelfinavir; intracellular;
D O I
10.1097/01.fpc.0000172241.42546.d3
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Objectives The human immunodeficiency virus protease inhibitor nelfinavir is substrate of polyspecific drug transporters encoded by ABCB1 (P-glycoprotein), ABCC1 (MRP1) and ABCC2 (MRP2), and an inhibitor of BCRP encoded by ABCG2. Genetic polymorphism in these genes may be associated with changes in transport function. Methods A comprehensive evaluation of single nucleotide polymorphisms (39 SNPs in ABCB1, 7 in ABCC1, 27 in ABCC2, and 16 in ABCG2), and inferred haplotypes was done to assess possible associations of genetic variants with cellular exposure of nelfinavir in vivo. Analysis used peripheral mononuclear cells from individuals receiving nelfinavir (n = 28). Key results were re-examined in a larger sample size (n = 129) contributing data on plasma drug levels. Results and conclusions There was no significant association between cellular nelfinavir area under the curve (AUC) and SN Ps or haplotypes at ABCC1, ABCC2, ABCG2. There was an association with cellular exposure for two loci in strong linkage disequilibrium: ABCB1 3435C>T; AUC(TT)>AUC(CT)> AUC(CC) (ratio 2.1, 1.4, 1, P-trend = 0.01), and intron 26 + 80T > Q AUC(CC)> AUC(CT) > AUC(TT) (ratio 2.4,11.3, 1, P-trend = 0.006). Haplotypic analysis using tagging SNPs did not improve the single SNP association values.
引用
收藏
页码:599 / 608
页数:10
相关论文
共 46 条
  • [1] MDR1 genetic polymorphism does not modify either cell permissiveness to HIV-1 or disease progression before treatment
    Bleiber, G
    May, M
    Suarez, C
    Martinez, R
    Marzolini, C
    Egger, M
    Telenti, A
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (04) : 583 - 586
  • [2] Mammalian ABC transporters in health and disease
    Borst, P
    Elferink, RO
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 2002, 71 : 537 - 592
  • [3] Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response
    Brumme, ZL
    Dong, WWY
    Chan, KJ
    Hogg, RS
    Montaner, JSG
    O'Shaughnessy, MV
    Harrigan, PR
    [J]. AIDS, 2003, 17 (02) : 201 - 208
  • [4] Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry
    Colombo, S
    Beguin, A
    Telenti, A
    Biollaz, J
    Buclin, T
    Rochat, B
    Decosterd, LA
    [J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2005, 819 (02): : 259 - 276
  • [5] COLOMBO S, UNPUB ARE PLASMA LEV
  • [6] Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection
    Csajka, C
    Marzolini, C
    Fattinger, K
    Décosterd, LA
    Fellay, J
    Telenti, A
    Biollaz, J
    Buclin, T
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (01) : 20 - 30
  • [7] Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)
    Doyle, LA
    Ross, DD
    [J]. ONCOGENE, 2003, 22 (47) : 7340 - 7358
  • [8] Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition
    Dresser, GK
    Spence, JD
    Bailey, DG
    [J]. CLINICAL PHARMACOKINETICS, 2000, 38 (01) : 41 - 57
  • [9] Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study
    Fellay, J
    Marzolini, C
    Meaden, ER
    Back, DJ
    Buclin, T
    Chave, JP
    Decosterd, LA
    Furrer, H
    Opravil, M
    Pantaleo, G
    Retelska, D
    Ruiz, L
    Schinkel, AH
    Vernazza, P
    Eap, CB
    Telenti, A
    [J]. LANCET, 2002, 359 (9300) : 30 - 36
  • [10] Ford J, 2004, ANTIVIR THER, V9, P77